Rojo EA, Escamilla LP, Rodríguez SR, Medina AL, García FMI, Ramírez DLOL, López MI, Wong AC, Rodríguez MA, Rivero AV, Medina BA, Quiroz MJ, González VM, Cruz ON, Núñez GT, Barrera BG, González DF, Hernández RL, Ramírez GE

Language: Spanish
References: 4
Page: 62-66
PDF size: 214.99 Kb.

ABSTRACT

On November 2021 a new SARS-CoV-2 variant of concern (VoC), named Omicron (B.1.1.529) was reported. This variant draw attention for its high number of mutations on the S protein. We present a 51 year old male, from South Africa who started with respiratory symptoms 48 hours after his arrival to Mexico City. During his stay at the ER a positive antigen and positive RT-qPCR were obtained. Minimal laboratory alterations were observed with no evidence of lung involvement on the CT scan. The outcome was favorable and was discharged six days later. On November 29, a notification from InDRE was received, reporting that the sequence obtained was compatible with SARS-CoV-2 Omicron variant.

REFERENCES

1. Karim SSA, Karim QA. Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic [published online ahead of print, 2021 Dec 3]. Lancet. 2021;398(10317):2126-2128. doi: 10.1016/S0140-6736(21)02758-6.

2. Chen J, Wang R, Gilby NB, Wei GW. Omicron (B.1.1.529): Infectivity, vaccine breakthrough, and antibody resistance. J Chem Inf Model. 2022.

3. Kandeel M, Mohamed MEM, Abd El-Lateef HM, Venugopala KN, El-Beltagi HS. Omicron variant genome evolution and phylogenetics. J Med Virol. 2021. doi: 10.1002/jmv.27515.

4. ViralZone [Internet]. ViralZone; SARS-CoV-2, Variantes [citado 24 dic 2021]. Available in: https://viralzone.expasy.org/9556